{"id":119199,"date":"2026-06-30T09:11:10","date_gmt":"2026-06-30T09:11:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/119199\/"},"modified":"2026-06-30T09:11:10","modified_gmt":"2026-06-30T09:11:10","slug":"trump-low-cost-glp-1-plan-a-likely-boost-for-eli-lilly-novo-nordisk","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/119199\/","title":{"rendered":"Trump low-cost GLP-1 plan a likely boost for Eli Lilly, Novo Nordisk"},"content":{"rendered":"

WASHINGTON \u2014 The Trump administration\u2019s grand bargain with drugmakers<\/a> on GLP-1s was based on a simple premise: lower prices in exchange for higher sales volume. Instead, the companies secured higher volume without the lower prices in some cases.<\/p>\n

When President Trump\u2019s team of negotiators got Eli Lilly and Novo Nordisk to agree to a monthly $245 price in Medicare and Medicaid in November, that price was supposed<\/a> to be<\/a> for all GLP-1s, including those for obesity, which until then had not been covered by Medicare.<\/p>\n

But that price was contingent on private Medicare insurers agreeing to cover the drugs for all uses, with a $50 copay. The administration did not publicly mention that condition, but Novo and Lilly recently confirmed it to STAT.\u00a0<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily intelligence on Capitol Hill and the life sciences industry \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"WASHINGTON \u2014 The Trump administration\u2019s grand bargain with drugmakers on GLP-1s was based on a simple premise: lower…\n","protected":false},"author":2,"featured_media":119200,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2759,184,5794,12661,59179,272,358,987,359],"class_list":["post-119199","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-biotechnology","tag-donald-trump","tag-drug-prices","tag-medicare","tag-medicare-negotiation","tag-novo-nordisk","tag-pharmaceuticals","tag-policy","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116838287775935774","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/119199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=119199"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/119199\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/119200"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=119199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=119199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=119199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}